摘要
目的:探讨曲美布汀联合阿普唑仑对腹泻型肠易激综合征(IBS-D)患者血清炎症因子、免疫功能、胃肠激素、脑肠肽及生活质量的影响。方法:选取IBS-D患者117例,随机分为对照组(n=58)和治疗组(n=59)。对照组仅给予曲美布汀治疗,治疗组给予曲美布汀联合阿普唑仑治疗,两组均连续治疗4周。检测并比较治疗前后两组患者血清炎症因子、免疫功能、胃肠激素指标和脑肠肽指标水平变化;统计并分析治疗前后两组SF-36生活质量评分。结果:治疗后两组的MOT、GAS、SP、5-HT、IL-8、IL-12、CD8+T细胞比例水平均显著下降(P<0.05或P<0.01),VIP、SS、CCK、CGRP、IL-10、CD3+、CD4+、CD4+/CD8+水平和SF-36评分均显著升高(P<0.05或P<0.01),且组间差异显著(P<0.05或P<0.01)。结论:曲美布汀联合阿普唑仑可显著改善IBS-D患者胃肠蠕动功能,平衡机体炎症因子水平,提高患者免疫功能和生活质量,疗效显著,值得临床推广应用。
Objective: To evaluate the effect of trimebutine combined with alprazolam on serum inflammatory factor,immune function,gastrointestinal hormone,ghrelin and quality of life of IBS-D patients. Methods: 117 cases of IBS-D were randomly divided into control group( n = 58) and treatment group( n = 59).The control group was only given trimebutine treatment,the treatment group was treated with trimebutine combined with alprazolam,2 groups were consecutively treated for 4 weeks. Detected and compared of the 2 groups of serum inflammatory factors,immune function,gastrointestinal hormon,ghrelin and quality of life changes before and after treatment; Statistics and analysis of 2 groups of SF-36 quality of life scores before and after treatment. Results: After treatment,the MOT,GAS,SP,5-HT,IL-8,IL-12,CD8+T cell ratio of 2 groups were significantly decreased( P <0.05 or P < 0.01),VIP,SS,CCK,CGRP,IL-10,CD3+,CD4+,CD4+/CD8+and SF-36 scores increased significantly( P < 0. 05 or P < 0. 01),and the difference between 2 groups was significant( P <0.05 or P < 0. 01). Conclusion: Trimebutine combined with alprazolam can significantly improve gastrointestinal peristaltic function of IBS-D patients,balance the level of inflammatory cytokines,improve the immune function and quality of life,with significant curative effect and worthy of clinical application.
出处
《河北医学》
CAS
2017年第11期1799-1802,共4页
Hebei Medicine
基金
河北省保定市科学技术研究与发展指导计划
(编号:16ZF094)